Metabolic Reprogramming: A Friend or Foe to Cancer Therapy?

Area of Science:

• Oncology
• Cancer Metabolism
• Cellular Biology

Background:

• Drug resistance is a primary reason for cancer treatment failure, often due to cancer cells escaping therapy-induced cell death.
• While apoptosis evasion is well-studied, drug resistance mechanisms are complex, involving pathways beyond cell death, including metabolic reprogramming.
• Mitochondria play a critical role in coordinating cellular responses to stress and maintaining homeostasis, influencing both metabolism and apoptosis.

Purpose of the Study:

• To review the multifaceted role of cancer metabolism in mediating drug resistance.
• To explore the potential of exploiting metabolic vulnerabilities to enhance cancer treatment efficacy.
• To highlight novel therapeutic avenues for overcoming drug resistance by targeting metabolic pathways.

Main Methods:

• Literature review of recent discoveries in cancer metabolism and drug resistance.
• Analysis of the interplay between cellular metabolism, mitochondrial function, and cancer cell survival under cytotoxic stress.
• Examination of how metabolic adaptations contribute to resistance against various cancer therapies.

Main Results:

• Cancer cells rewire cellular metabolism to support proliferation and survival under therapeutic pressure.
• Mitochondria are central to coordinating metabolic and apoptotic homeostasis, facilitating resistance.
• Metabolic pathways are co-opted by cancer cells to evade cell death and promote survival during treatment.

Conclusions:

• Metabolic reprogramming is a critical mechanism underlying cancer drug resistance.
• Targeting specific metabolic pathways and dependencies presents a promising strategy to overcome treatment resistance.
• Exploiting metabolic vulnerabilities offers new opportunities for developing more effective cancer therapies.